autologous blood and marrow transplantation - Blog Science ...

494 Chapter 9: Long-Term Effects
ABMT IN AL
Engraftment on PMN according to status
r f
' J
63 ±4
•
i •
* 1 ... CR1 (n=153)
41 ±8 — CR2+(n=41)
t j
i \
J 1
•_
p =0.023
0 1 2 3 4 5 6 7
Months
CTU Paris, St Antoine
Figure 1
29 days (10-153) in AML. Recovery of platelets was 39 days (15-766) vs. 70 days
(18-1054).
2) Doses of marrow submitted to purging with mafosfamide. Patients receiving
higher doses engrafted more rapidly (Table 5): at 30 days posttransplant, 66 ± 5%
patients receiving the higher marrow doses were successfully grafted vs. 51 ± 5%
in those receiving the lower doses. Similarly, the probabilities for engraftment of
platelets at 6 months were 78 ± 5% vs. 65 ± 6% (Table 6).
3) Use of the adjusted-dose technique for purging. Patients receiving marrow
purged with this technique engrafted more quickly on platelets than those receiving
marrow purged with the constant dose of 50 pg/mL (Fig. 3).
4) Cryopreservation efficiency: patients receiving marrow "well" cryopreserved
(efficiency above median value) had a higher probability of engraftment for PMN at
day 30 (73 ± 5% vs. 51 ± 6%). There was no impact on platelet engraftment (Table 7).
Outcome
The marrow dose submitted to purging (the graft itself) influenced TRM, LFS,
and overall survival (OS) (Fig. 4), but not the relapse incidence. The technique of